Becomes the first subcutaneously administered PD-1 inhibitor.

Demonstrates its commitment to providing quality, cost-saving treatment options to clinicians and the patients they serve.

Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.

Novo Nordisk will soon acquire from Novo Holdings Catalent’s three fill-finish sites located in Italy, the U.S., and Belgium.

Will support clinical development of Nirsum’s lead development candidate, NRS-033.

Evidence of efficacy and safety data support the potential for vatiquinone to fill the significant unmet need for patients ...

A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...

Prasinezumab continues to be well tolerated and no new safety signals were observed.

Adicet Bio Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies ...

Biomedicines as part of its efforts to drive growth and innovation in the biopharmaceutical sector. Established in 2021 and ...

With a total area exceeding 16,000 square meters, the new facility houses the company's production, quality, data, and ...

Dr. Marc Damelin possesses extensive industry experience in oncology drug discovery and development across a variety of ...